证券之星消息，8月5日，热景生物（688068）融资买入4279.76万元，融资偿还3906.82万元，融资净买 入372.94万元，融资余额2.99亿元，近3个交易日已连续净买入累计5630.15万元，近20个交易日中有13 个交易日出现融资净买入。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-05 | 372.94万 | 2.99亿 | 1.43% | | 2025-08-04 | 3413.39万 | 2.95 Z | 1.43% | | 2025-08-01 | 1843.83万 | 2.61亿 | 1.30% | | 2025-07-31 | -640.08万 | 2.43亿 | 1.34% | | 2025-07-30 | 130.27万 | 2.49亿 | 1.41% | | 交易日 | 两融余额(元) | 余额变动 (元) | 变动幅度 | | --- | --- | --- | --- | | 2025-08-05 | 2.99亿 | 372.94万 | 1.26% | | 2025-08 ...

Group 1 - The stock price of Hotgen Biotech (688068) closed at 226.0 CNY on August 5, 2025, with an increase of 1.25% and a turnover rate of 2.93% [1] - The company experienced a net outflow of main funds amounting to 24.24 million CNY, accounting for 4.02% of the transaction amount, with significant outflows from large orders [1] - The latest quarterly report shows total revenue of 93.24 million CNY, a year-on-year decrease of 19.71%, and a net profit attributable to shareholders of 24.01 million CNY, a significant decline of 574.96% [1] Group 2 - Hotgen Biotech has made investments in 21 companies and participated in 446 bidding projects, indicating active engagement in the market [2] - The company holds 85 trademark registrations and 90 patents, showcasing its focus on intellectual property [2] - Additionally, Hotgen Biotech possesses 175 administrative licenses, reflecting its compliance and operational capabilities [2]

Core Viewpoint - The major shareholder of Beijing Hotgen Biotech Co., Ltd. has completed a share reduction plan, selling a total of 1,796,980 shares, which is approximately 1.9383% of the company's total share capital, due to personal financial needs [2][4]. Group 1: Major Shareholder's Holdings - Before the reduction plan, the major shareholder, Zhou Xin, held 6,806,629 shares, accounting for 7.3420% of the company's total share capital [1]. Group 2: Reduction Plan Implementation - The reduction plan was disclosed on June 26, 2025, with a maximum intended reduction of 1,800,000 shares, representing up to 1.9416% of the total share capital [2]. - The actual reduction was completed by August 4, 2025, with Zhou Xin having sold 1,796,980 shares, achieving the planned reduction [2][4]. - The reduction plan was terminated early by the shareholder, indicating that the planned reduction was fully executed [4].

证券代码：688068 证券简称：热景生物 公告编号：2025-055 北京热景生物技术股份有限公司 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 大股东持有的基本情况 本次减持计划实施前，北京热景生物技术股份有限公司（以下简称"公司"） 股东周锌持有公司股份 6,806,629 股，占公司总股本的 7.3420%。上述股东所持 股份来源于公司首次公开发行前持有及资本公积转增股本取得，已上市流通。 ? 减持计划的实施结果情况 《北京热景生物技术股份有限公司关于持股 5%以上股东减持股份计划公告》 $$(\angle_{\Delta}$$ 告编号：2025-047）。股东周锌因自身资金需求，拟通过集中竞价或大宗交易的 方式减持公司股份合计不超过 1,800,000 股，拟减持比例不超过公司总股本的 截至 2025 年 8 月 4 日，股东周锌通过集中竞价和大宗交易的方式合计减持公司 股份 1,796,980 股，占公司总股本的 1.9383%。现将有关减持结果情况公告如下： 一、减持主体减持 ...

热景生物（SH 688068，收盘价：223.21元）8月4日晚间发布公告称，公司于2025年8月4日收到股东周 锌发来的《股份减持结果的告知函》。截至2025年8月4日，股东周锌通过集中竞价和大宗交易的方式合 计减持公司股份约180万股，占公司总股本的1.9383%。本次减持计划实施完毕。 2024年1至12月份，热景生物的营业收入构成为：体外诊断产品占比98.85%，其他业务占比1.15%。 （文章来源：每日经济新闻） ...

北京热景生物技术股份有限公司 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 证券代码：688068 证券简称：热景生物 公告编号：2025-055 重要内容提示： 大股东持有的基本情况 本次减持计划实施前，北京热景生物技术股份有限公司（以下简称"公司"） 股东周锌持有公司股份 6,806,629 股，占公司总股本的 7.3420%。上述股东所持 股份来源于公司首次公开发行前持有及资本公积转增股本取得，已上市流通。 减持计划的实施结果情况 2025 年 6 月 26 日，公司于上海证券交易所网站（www.sse.com.cn）披露了 《北京热景生物技术股份有限公司关于持股 5%以上股东减持股份计划公告》（公 告编号：2025-047）。股东周锌因自身资金需求，拟通过集中竞价或大宗交易的 方式减持公司股份合计不超过 1,800,000 股，拟减持比例不超过公司总股本的 1.9416%。公司于 2025 年 8 月 4 日收到股东周锌发来的《股份减持结果的告知函》。 截至 2025 年 ...

格隆汇8月4日丨热景生物(688068.SH)公布，公司于2025年8月4日收到股东周锌发来的《股份减持结果 的告知函》。截至2025年8月4日，股东周锌通过集中竞价和大宗交易的方式合计减持公司股份1,796,980 股，占公司总股本的1.9383%。 ...

资料显示，永赢医药健康在今年二季度的前十大重仓股为舒泰神、热景生物、益方生物、泰恩康、奥赛 康、康辰药业、荣昌生物、神州细胞、迪哲医药、汇宇制药。从股价走势看，其第一大重仓股舒泰神单 月涨幅近40%，如果从5月份开始，该股在三个月的时间里股价涨幅竟然高达5倍。而第二和第三大重仓 股也在7月份分别上涨了近40%和45%以上。 永赢医药健康的现任基金经理为单林，其在今年3月份开始管理该基金，4月8日独自管理至今。从履历 上看，单林始终坚守在医药研究领域，其曾任东方证券股份有限公司医药研究员；长江证券股份有限公 司医药研究员，2023年加入永赢基金管理有限公司。 财通集成电路产业股票则由金梓才管理，其现任财通基金管理有限公司党委委员、副总经理、权益投资 总监、基金投资部总经理、基金经理，累计管理公募基金将近11年。今年二季报显示，其持有的前十大 重仓股为仕佳光子、生益电子、新易盛、中际旭创、天孚通信、太辰光、工业富联、长芯博创、德科 立、汇绿生态。尽管与一季度相比已经全部变更，但好在仕佳光子、新易盛、中际旭创等多只个股的单 月涨幅都超过了40%，极大拉动的该基金业绩表现。 今年以来，生物医药板块持续大涨，令众多医药 ...

Group 1 - The 2025 version of the chikungunya treatment plan has been released, leading to a rise in companies like Lide Man and Rejing Bio, boosting the medical device sector [1] - The medical device ETF (562600) closed up by 0.67% [1] - The 11th batch of centralized procurement has been initiated, with the National Medical Insurance Administration announcing measures to alleviate low-price competition in the industry [1] Group 2 - The National Medical Products Administration released measures in early July to support the innovation and development of high-end medical devices [1] - There is a positive outlook for innovative drugs and devices due to clear policy support in regulation and payment, which is expected to accelerate the development of domestic high-end devices [1] - The medical device ETF (562500) has a brain-computer interface component of 22.72%, leading the market and is expected to benefit from the growing interest in brain-computer interfaces [1]

Market Overview - On August 1, the medical device sector rose by 0.18% compared to the previous trading day, with Lidman leading the gains [1] - The Shanghai Composite Index closed at 3559.95, down 0.37%, while the Shenzhen Component Index closed at 10991.32, down 0.17% [1] Top Gainers in Medical Device Sector - Lidman (300289) closed at 8.45, up 20.03% with a trading volume of 588,100 shares and a transaction value of 496 million yuan [1] - Rejing Bio (688068) closed at 216.50, up 11.03% with a trading volume of 44,000 shares and a transaction value of 948 million yuan [1] - Guanwu Bio (300238) closed at 19.00, up 9.20% with a trading volume of 470,900 shares and a transaction value of 878 million yuan [1] - Yingke Medical (300677) closed at 37.28, up 8.53% with a trading volume of 447,500 shares and a transaction value of 1.643 billion yuan [1] - Other notable gainers include Zhonghong Medical (300981), Sainuo Medical (688108), and Kemei Diagnosis (688468) with respective increases of 8.05%, 6.70%, and 6.66% [1] Top Losers in Medical Device Sector - Huakang Clean (301235) closed at 33.10, down 5.97% with a trading volume of 158,600 shares [2] - Kangtai Medical (300869) closed at 19.80, down 4.35% with a trading volume of 284,800 shares and a transaction value of 571 million yuan [2] - Other significant decliners include XD Chunli Medical (688236), Haooubo (688656), and Huqiang Technology (688151) with respective declines of 3.67%, 3.13%, and 3.10% [2] Capital Flow in Medical Device Sector - On the same day, the medical device sector saw a net inflow of 40.108 million yuan from institutional investors, while retail investors experienced a net outflow of 93.3185 million yuan [2][3] - Notable net inflows from institutional investors included Lepu Medical (300003) with 57.2395 million yuan and Guanwu Bio (300238) with 57.033 million yuan [3] - Conversely, significant net outflows from retail investors were observed in Lepu Medical (-82.3375 million yuan) and Guanwu Bio (-11.5 million yuan) [3]